Haoxi Health Technology Business Summary

Haoxi Health Technology Ltd (HAO) operates as a specialized online marketing service provider in China, primarily generating revenue through the delivery of short-video and customized marketing solutions for the healthcare industry. The company’s business model is built on a transaction-based service fee structure where it plans, produces, and optimizes digital advertisements across major Chinese social media and video platforms, including Douyin, WeChat, and Toutiao. Its primary business segments are divided into short-video marketing solutions and comprehensive customized marketing services, which focus on consumer acquisition and retention for healthcare advertisers. In the competitive landscape, Haoxi contends with players such as ZW Data Action Technologies, Inc. (CNET), Baosheng Media Group Holdings Ltd. (BAOS), and China Communications Services Corp. Ltd. Within this peer group, Haoxi distinguishes itself as a niche micro-cap specialist focused on the high-growth intersection of healthcare and short-form video content, though it currently faces significant volatility relative to its larger diversified competitors. The company is led by a management team with extensive experience in China’s digital media and healthcare sectors. Zhen Fan serves as the Chairman and Chief Executive Officer, bringing over 15 years of industry experience including prior leadership roles as CEO of MMTEC, Inc. and media specialist positions at Sohu.com. Lei Xu, the Chief Operating Officer and Director, contributes over a decade of expertise in healthcare-specific marketing, having previously spearheaded medical advertising initiatives for regional television networks. The financial leadership was recently transitioned to Dongxue Li, who was appointed Chief Financial Officer in April 2025 following her tenure as a financial reporting manager within the company’s subsidiaries. While the firm is predominantly retail-owned, it maintains a board of independent directors including Jia Liu, Changmao Su, and Jianbing Zhang, and has attracted minor institutional positions from firms such as Citadel Advisors and UBS Group.